Arch Biopartners Inc V.ARCH

Severely undervalued

[2019champs]

We are severely undervalued and that's an understatement. We are in a 20B market space. We have a drug that had it's best phase 1 data in the kidneys and we are running a phase 2 trial that will give us data for the lungs. Yes, the vaccines are out but there are many folks who have been impacted by covid19 well before the vaccines were rolled out. Some of these people have to deal with long term effects of aki, lung injury, and liver complications. We potentially have a treatment for that. Now, lets look past covid. Sepsis, surgery, aki from other medical complications, lung & liver inflammation from other complications. The market is huge. Even a 5% market share puts as at a Billion dollar valuation. We are currently trading around 67M usd market cap. This trial was expanded to include more patients and more hospitals. Are they really going to expand a trial for a drug that's not working? I will say it again. Extremely undervalued.

[Antonius2]

Researchers may also be interested in showing that the experimental drug works for additional groups of people with conditions other than that for which the drug was initially developed. For example, they may be interested in testing a drug for inflammation on people with Covid 19. In normal circumstances, the drug would have already have proven safe and obtained marketing approval during